CoChat

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide in the USA. METHODS: Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective. RESULTS: More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints. The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg. The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg. For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg. CONCLUSIONS: The cost of bringing one patient to the triple composite endpoint of an HbA1c < 7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg relative to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Once-weekly semaglutide therefore provides better value for money than dulaglutide for the treatment of people with T2D in the USA. FUNDING: Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-018-0402-8

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Design of the SUSTAIN 7 randomized controlled trial
Fig. 1 Design of the SUSTAIN 7 randomized controlled trialCC BY-NC · PubMed Central
Fig. 2 Numbers needed to treat to bring one patient to target with once-weekly semaglutide 0.5 and 1.0 mg, and dulaglutide 0.75 and 1.5 mg. HbA1c, glycated hemoglobin
Fig. 2 Numbers needed to treat to bring one patient to target with once-weekly semaglutide 0.5 and 1.0 mg, and dulaglutide 0.75 and 1.5 mg. HbA1c, glycated hemoglobinCC BY-NC · PubMed Central
Fig. 3 Relative cost of control with once-weekly semaglutide 0.5 mg, dulaglutide 0.75 mg, and dulaglutide 1.5 mg versus once-weekly semaglutide 1.0 mg (index = 100). HbA1c, glycated hemoglobin
Fig. 3 Relative cost of control with once-weekly semaglutide 0.5 mg, dulaglutide 0.75 mg, and dulaglutide 1.5 mg versus once-weekly semaglutide 1.0 mg (index = 100). HbA1c, glycated hemoglobinCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 21

Metadata

Authors
Wilkinson, L., Hunt, B., Johansen, P., Iyer, N. N., Dang-Tan, T., & Pollock, R. F.
Affiliations
Novo Nordisk (Denmark) (DK)
Corresponding author
Pollock, Richard F.
Venue
Diabetes Therapy
Published
2018-03-19
Volume
9
Issue
3
Pages
951-961
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2794276124
Cited by
18
References
25
Citations by year
2026: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 5 · 2018: 2
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
semaglutide, dulaglutide, weight loss, cost per patient, number needed to treat, GLP-1 receptor agonists, healthcare payer perspective, cost-effectiveness, glycemic control, weight gain, hypoglycemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. https://app.cochat.ai/papers/10.1007/s13300-018-0402-8
The paper
Wilkinson, L., Hunt, B., Johansen, P., Iyer, N. N., Dang-Tan, T., & Pollock, R. F. (2018). Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy. https://doi.org/10.1007/s13300-018-0402-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.